• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Dermatology

Enteral glutamine does not reduce the time to discharge for severe burns

byAndrew LeeandKiera Liblik
September 16, 2022
in Dermatology, Emergency
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. No significant difference was seen in severe burn patient time to discharge between a glutamine treatment group compared to a placebo control group. 

2. The glutamine group had a slightly higher six-month mortality rate than the placebo group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Glutamine is implicated in key stress-response pathways. Further, these pathways are upregulated in serious illnesses and injuries such as severe burns. The present study compared the use of glutamine to a non-isonitrogenous placebo in patients with severe burn injuries. There was no significant difference in the time to discharge alive between the two groups. The results did not change when adjusted for burn site or other covariates. Although, the six-month mortality rate was slightly higher in the glutamine group compared to the placebo group. Tertiary outcomes such as in-hospital mortality, length-of-stay variables, and incidence of bacteremia due to gram-negative organisms were not significantly different between the two groups. At the six-month evaluation, no differences were seen in health-related quality-of-life scores, activities of daily living, or instrumental activities of daily living. The rate of serious adverse events was similar in the two groups. The results from this study do not support the use of glutamine in patients with severe burn injuries. The strength of this study was its large study population and methodological rigor which further increases study generalizability and validity.

Click to read the study in NEJM

Relevant Reading: A randomized trial of glutamine and antioxidants in critically ill patients

In-Depth [randomized controlled trial]: The RandomizEd Trial of ENtERal Glutamine to minimIZE Thermal Injury (RE-ENERGIZE) trial is an international, multicenter, randomized controlled trial comparing the effect of enteral glutamine to a placebo control in adults with severe burns. Adults aged 18 years of age and older with second or third-degree burns were enrolled in the study. The definition of a major burn was defined according to age groups: 20% or more of total body surface area (TBSA) for patients 18 to 39 years or 15% or more when concomitant inhalation injury was present; 15% or more of TBSA for patients 40 to 59 years; and 10% or more of TBSA for patients 60 years and older. Patients were randomized to receive either glutamine every four hours orally or by feeding tube for a total of 0.5 grams per kilogram of pre-burn body weight per day. The placebo group received isocaloric maltodextrin mixed with water, other liquids, or food. The median time to discharge was not significantly different between the glutamine (40 days) and placebo group (38 days) (95% Confidence Interval [CI], 0.80 to 1.04; p=0.17). The six-month mortality for the glutamine group was 17.2% and for the placebo group was 16.2% (95% CI, 0.80 to 1.41). There were no significant differences in tertiary outcomes. Urea levels were slightly elevated in the glutamine treatment group, but there was no substantial difference in the rate of acute kidney injury or use of renal-replacement therapy. No significant difference in severe adverse events was seen between groups. In summary, the present study suggests that enteral glutamine is not a suitable management strategy for severe burn patients.

RELATED REPORTS

High emergency department pediatric readiness associated with decreased mortality

2 Minute Medicine Rewind January 16, 2023

Clinical decision-making strategy improves acute heart failure outcomes

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: acute carebacteremiaburn patientsdematologyemergencyenteral glutamineglutamineintensive care unitRE-ENERGIZE trialsevere burns
Previous Post

Wellness Check: Sleep

Next Post

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

RelatedReports

Quick Take: Impact of scribes on emergency medicine doctors’ productivity and patient throughput: multicentre randomised trial
Emergency

High emergency department pediatric readiness associated with decreased mortality

January 16, 2023
Compliance-linked incentives increase infant immunizations rates in rural India
Weekly Rewinds

2 Minute Medicine Rewind January 16, 2023

January 16, 2023
Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial
Cardiology

Clinical decision-making strategy improves acute heart failure outcomes

January 12, 2023
Nearly Half of All Pediatric Buprenorphine Exposures Result in Hospitalization
Emergency

Higher rate of adverse events following abortion induced by mifepristone-misoprostol than procedurally

January 10, 2023
Next Post
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

VEGFR-targeted ultrasound may improve detection of pancreatic cancer

Aggressive hydration does not improve clinical outcomes in acute pancreatitis

Parents often unaware of adolescents’ suicidal thoughts

Total antioxidant intake in diet inversely related to depression in adolescent girls

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options